Steady-state pharmacokinetics of tacrine in long-term treatment of alzheimer patients

Dementia and Geriatric Cognitive Disorders

Volumn 7, Issue 2, 1996, Pages 111-117

  Johansson, Monika ^a   Hellström Lindahl, Ewa ^b   Nordberg, Agneta ^b  

^a MEDICAL PRODUCTS AGENCY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acetylcholinesterase activity; Alzheimer s disease; Cerebrospinal fluid; Long term treatment; Pharmacokinetics; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; TACRINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID LEVEL; CHOLINESTERASE BLOOD LEVEL; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; ENZYME ACTIVITY; ERYTHROCYTE LEVEL; FEMALE; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; TACRINE; TIME FACTORS;

EID: 0030061024     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000106863     Document Type: Article

References (29)

1. Eagger SA, Levy R, Sahakian BJ: Tacrine in Alzheimer's disease. Lancet 1991:337:989-992.
2. Davies KL, Thai LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SL et al: A double-blind placcbo-conl rolled multiccntcr study of tacrine for Alzheimer’s disease. N Eng J Med 1992: 327:1253-1259.
3. Farlow M, Gracon SL, Hershcy LA, Lewis KW, Sadosky CH, Dolan-Ureno J: A controlled trial of tacrine in Alzheimer's disease. JAMA 1992; 268:2523-2529.
4. Wagstaff AJ, McTavish D: Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in Alzheimer's disease. Drugs Aging 1994:4:510-540.
5. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI: A 3-weck randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994;271:985-991.
6. Nordberg A, Lilja A, Lundqvist H, Hartvig P, Amberla K, Viitanen M, Warpman U, Johansson M, Hellström-Lindahl E, Bjurling P, Fasth KJ, Längström B, Winblad B: Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography. Neurobiol Aging 1992; 13:747-758.
7. Nordberg A: Effect of long-term treatment with tacrine (THA) in Alzheimer’s disease as visualized by PET. Acta Neurol Scand SuppI 1993; 149:62-65.
8. Hartvig P, Askmark H, Aquilonius S-M, Wiklund L, Lindström B: Clinical pharmacokinetics of intravenous and oral 9-amino-1,2,3,4-tctrahydroacridinc, tacrine. Eur J Clin Pharmacol’ 1990:38:259-263.
9. Hartvig P, Pettersson E, Wikiund L, Lindström B: Pharmacokinetics and effects of 9-amino-1.2,3.4-tetrahydroacridine in the immediate postoperative period in neurosurgical patients. J Clin Anesth 1991:3:137-142.
10. Forsyth DR, Wilcock GK, Morgan RA, Truman CA, Ford JM, Roberts CJC: Pharmacokinetics of tacrine hydrochloride in Alzheimer’s disease. Clin Pharmacol Ther 1989,46:634-641.
11. Cutler NR, Scdman AJ, Prior P, Underwood BA, Selen A, Balogh L, Kinkel AK, Gracon SI, Gamzu ER: Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease. Psvchopharmaeol Bull 1990:26:231-234.
12. Ählin A, Adem A, Junthé T, Öhntan G, Nvbäck H: Pharmacokinetics of tetrahydroami-noacridine: relations to clinical and biochemical effects in Alzheimer patients. Ini Clin Psy-chopharmacol 1992:7:29-36.
13. Nybäck H, Nyman H, Öhman G, Nordgren I, Lindström B: Preliminary experiences and results with THA for the amelioration of symptoms of Alzheimer’s disease: in Giacobini E. Becker R (eds): Current Research in Alzheimer Therapy. New York. Taylor & Francis. 1988. pp 231-236.
14. Seien A, Balogh L, Siedlik P, Posvar E, Kinkel A, Welling P: Pharmacokinetics of tacrine in healthy subjects. Pharmacol Res 1988:5:S-21S.
15. Askmark H, Aquilonius S-M, Gillberg P-G, Hartvig P, Hilton-Brown P, Lindström B, Nilsson D, Stälhcrg E, Winkler T: Functional and pharmacokinetic studies of telrahydroamino-acridine in patients with amyotrophic lateral sclerosis. Acta Neurol Scand 1990:82:253-258.
16. Johansson IM, Nordberg A: Pharmacokinetic studies of Cholinesterase inhibitors. Acta Neurol Scand Suppl 1993:149:22-25.
17. Truman CA, Ford JM, Roberts CJC: Comparison of the chromatographic characteristics of metabolites of tacrine hydrochloride in human scrum and urine with those of in vitro metabolic products from hepatic microsomcs. Biochem Pharmacol 1991:42:956-959.
18. Madden S, Wolf TF, Pool WF, Park BK: An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Studies with human and rat liver microsomcs. Biochcm Pharmacol 1993: 46:13-20.
19. Puri SK, Hsu RS, Ho I, Lassman HB: Singledose safety, tolerance and pharmacokinetics of HP 029 in elderly men: a potential Alzheimer agent. Curr Ther Res 1988:44:766-780.
20. Puri SK, Hsu RS, Ho I, Lasseman HB: Singledose safety, tolerance and pharmacokinetics of HP 029 in healthy young men: A potential Alzheimer agent. J Clin Pharmacol 1989:29:278-284.
21. McKhann G, Drachman D, Folslein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Service Task Force on Alzheimer's Disease. Neurology 1984:34:939-944.
22. Folslein M, Folslein S, McHugh P: Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975:12:189-198.
23. Amberla K, Nordberg A, Viitancn M, Winblad B: Long-term treatment with tacrine (THA) in Alzheimer’s disease - evaluation of neuropsychological data. Acta Neurol Scand Suppl 1993:149:55-57.
24. Shigcta M, Persson A, Viitancn M, Winblad B, Nordberg A: EEG regional changes during long-term treatment with tetrahvdroamino-acridinc (THA) in Alzheimer’s disease. Acta Neurol Scand Suppl 1993:149:58-61.
25. Ekman L, Lindström B, Roxin P: Determination of tacrine and the 1-hydroxy metabolite in plasma using HPLC. J Chromatogr 1989:494: 397-402.
26. Eltman GH, Courtney KD, Andres Jr. V., Fcalherstone RM: A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961:7:88-95.
27. Sherman KA: Pharmacodynamics of oral E2020 and tacrine in humans: Novel approaches: in Becker R. Giacobini E (eds): Cholinergic Basis for Alzheimer Therapy. Boston. Birkhäuser. 1991. pp 321-328.
28. Ford JM, Truman CA, Wilcock GK, Roberts CJC: Scrum concentrations of tacrine hydrochloride predict its adverse effects in Alzheimer's disease. Clin Pharmacol Ther 1993:53: 691-695.
29. Roberts C, Ford J, Mäkelä P, Truman C: Scrum tacrine concentrations too low. BMJ 1994: 308:1506.